Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Harris, T. L.
  • Lowery, Colin
  • Hixon, M. S.
  • Janda, Kim

publication date

  • August 2014

journal

  • ACS Chemical Neuroscience  Journal

abstract

  • Botulinum neurotoxicity is characterized by peripheral neuromuscular blockade/flaccid paralysis that can lead to respiratory failure and ultimately death. Current therapeutic options provide relief in a pre-exposure scenario, but there are no clinically approved postexposure medical countermeasures. Here, we introduce a platform that utilizes a combination of a toxin sequestering agent and a pharmacological antagonist to ablate botulinum neurotoxicity in a well-defined mouse lethality assay. The platform was constructed to allow for ready exchange of sequestering agent and/or pharmacological antagonist for therapeutic optimization. As such, we attempted to improve upon the pharmacological antagonist, a potassium channel blocker, 3,4-diaminopyridine, through a prodrug approach; thus, a complete kinetic decomposition pathway is described. These experiments provide the first proof-of-principle that a synergistic combination strategy can be used to reduce toxin burden in the peripheral using a sequestering antibody, while restoring muscle action via a pharmacological small molecule antagonist.

subject areas

  • 4-Aminopyridine
  • Animals
  • Botulinum Antitoxin
  • Botulinum Toxins
  • Drug Therapy, Combination
  • Female
  • Kinetics
  • Mice
  • Neurotoxicity Syndromes
  • Potassium Channel Blockers
  • Sequestering Agents
  • Survival Analysis
scroll to property group menus

Research

keywords

  • Botulinum neurotoxin
  • K+ channel blocker
  • antibody
  • drug combination
  • prodrug
scroll to property group menus

Identity

PubMed Central ID

  • PMC4140587

International Standard Serial Number (ISSN)

  • 1948-7193

Digital Object Identifier (DOI)

  • 10.1021/cn500135h

PubMed ID

  • 25000171
scroll to property group menus

Additional Document Info

start page

  • 632

end page

  • 636

volume

  • 5

issue

  • 8

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support